TitleB-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
Publication TypeJournal Article
Year of Publication2008
AuthorsCi, Weimin, Polo Jose M., and Melnick Ari
JournalCurr Opin Hematol
Date Published2008 Jul
KeywordsGene Expression Regulation, Neoplastic, Humans, Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-6, Transcription, Genetic

<p><b>PURPOSE OF REVIEW: </b>The B-cell lymphoma 6 transcriptional repressor is the most commonly involved oncogene in B-cell lymphomas. Sustained expression of B-cell lymphoma 6 causes malignant transformation of germinal center B cells. Understanding the mechanism of action of B-cell lymphoma 6 is crucial for the study of how aberrant transcriptional programming leads to lymphomagenesis and development of targeted antilymphoma therapy.</p><p><b>RECENT FINDINGS: </b>Identification of B-cell lymphoma 6 target genes indicates a critical role for B-cell lymphoma 6 in facilitating a state of physiological genomic instability required for germinal center B cells to undergo affinity maturation, and suggests its contribution to several additional cellular functions. The discovery of several layers of counterregulatory mechanisms reveals how B cells can control and fine-tune the potentially lymphomagenic actions of B-cell lymphoma 6. From the biochemical standpoint, B-cell lymphoma 6 can regulate distinct biological pathways through different cofactors. This observation explains how the biological actions of B-cell lymphoma 6 can be physiologically controlled through separate mechanisms and affords the means for improved therapeutic targeting. The fact that patients with B-cell lymphoma 6-dependent lymphoma can be identified on the basis of gene signatures suggests that therapeutic trials of B-cell lymphoma 6 inhibitors could be personalized to these individuals.</p><p><b>SUMMARY: </b>B-cell lymphoma 6 plays a fundamental role in lymphomagenesis and is an excellent therapeutic target for development of improved antilymphoma therapeutic regimens.</p>

Alternate JournalCurr Opin Hematol
PubMed ID18536578
PubMed Central IDPMC2748732
Grant ListR01 CA104348 / CA / NCI NIH HHS / United States
R01 CA104348-05 / CA / NCI NIH HHS / United States